AG真人官方

NEW YORK, June 2, 2025 /PRNewswire/ --听听(狈补蝉诲补辩: IMUX),听a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor, scientific and industry conferences in June:

• June 3-5:听Jefferies Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present a company overview on Thursday, June 5, 2025 at 4:55 pm ET at this conference in New York. A webcast will be available on the "Events and Presentations" section of Immunic's website at: .
  
  Dr. Vitt,听Jason Tardio, President and Chief Operating Officer, Glenn Whaley, Chief Financial Officer, and Jessica Breu, Vice President Investor Relations and Communications, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Jefferies representative or Jessica Breu at: [email protected].

• June 10-13:听4th RSC Anglo-Nordic Medicinal Chemistry Symposium. Christian Gege, Ph.D., Head of Intellectual Property at Immunic, will present preclinical data highlighting antiviral candidates based on lead asset vidofludimus calcium (IMU-838) in a flash talk and a poster presentation听at this symposium in Snekkersten, Denmark.
  • Poster Title:听DHODH Inhibitors Containing Carboxylic Acid Bioisosters With Superior Broad-Spectrum Antiviral Activity for Next Pandemic Preparedness
  • Poster/Flash Talk Number:听P18/FT18
  • Poster Session:听Displayed听throughout the event
  • Flash Talk Session Date:听Wednesday, June 11, 2025
  • Flash Talk Session Time:听1:45 pm 鈥� 2:30 pm CET (7:45 am 鈥� 8:30 am ET)
    
    
• June 11:听UBS Life Sciences Conference. Dr. Vitt and Ms. Breu will attend this conference in London, UK. To schedule a meeting, please contact Jessica Breu at: [email protected].
  
  
• June 16-19:听BIO International Convention 2025. Members of Immunic's management and business development teams will participate in partnering activities at this convention in Boston. To schedule a meeting, please use the , or contact Jessica Breu at: [email protected].
  
  
• June 21-24:听11th Congress of the European Academy of Neurology (EAN) 鈥� Helsinki 2025. Members of Immunic's management, medical and preclinical teams will attend this congress in Helsinki, Finland. The team will be available throughout the event at booth #E38. Additionally, data highlighting nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), will be presented in an ePresentation session.
  • Poster Title:听Vidofludimus Calcium Shows Potential Neuroprotective Effects in an In Vivo Multiple Sclerosis Model by Nurr1 Modulation
  • Presenting Author:听Evelyn Peelen, Ph.D., Head of Research at Immunic
  • Abstract ID:听A-25-14987
  • ePresentation Number: EPR-265
  • Session Name:听MS and Related Disorders 3
  • Session Date:听Monday, June 23, 2025
  • Session Time:听2:00 pm 鈥� 2:45 pm EEST (7:00 am 鈥� 7:45 am ET)
    
    
• June 23-25:听Accelerating Bio-Innovation (ABI) Conference 2025. Dr. Vitt and Mr. Tardio will attend this conference, organized in partnership with Royalty Pharma, in Cambridge, MA.

All presentations will be accessible on the "Events and Presentations" section of Immunic's website at: .

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: .

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor, scientific and industry conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine 鈥� Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
[email protected]

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
[email protected]

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
[email protected]

听

View original content to download multimedia:

SOURCE Immunic, Inc.